Inspire Biotherapeutics Inc. founded by Sandra Donaldson  is a promising biotech startup in Toronto, Ontario, on a mission to develop life-saving gene therapies for individuals suffering from monogenic and acquired lung diseases. With a proprietary AAVenger gene therapy platform, Inspire is targeting transduction and long-term expression in lung tissue without affecting other tissue types. This novel platform has demonstrated superior lung tropism and transduction efficiency of cells in the upper and lower respiratory tract of the lung, rapid and sustained expression of therapeutic transgenes, and is amenable to repeat dosing.

Inspire's business founders, C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine, are providing investment, corporate development, and commercialization strategy. Currently, Inspire is pursuing the initiation of a First-in-Human clinical trial for a lethal neonatal lung disease, which has a short time to data readout and a high probability of success. With the potential to also target Cystic Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis, and other monogenic lung diseases, Inspire Biotherapeutics is poised to become a game-changer in the biotech industry.